Streamex Corp. (STEX) Stock Score, Valuation & Financial Research

Streamex Corp. is in the Financial Services sector and Investment - Banking & Investment Services industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for STEX

Streamex Corp. does not currently have a complete Wall Street Score. The stored market price is USD 0.52. These figures are a research snapshot, not a buy or sell recommendation.

What Streamex Corp. does

Streamex Corp., previously known as BioSig Technologies, Inc., officially assumed its new name on September 12, 2025, after completing a merger with Streamex Exchange Corporation. The company has since pivoted its core business strategy, moving from healthcare technology to specialize in the tokenization of tangible assets. A primary objective of this shift is to integrate the gold and broader commodities markets into blockchain technology. To facilitate this, Streamex provides robust, institutional-level infrastructure for asset tokenization, which is uniquely underpinned by a treasury denominated in gold.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Streamex Corp. operates as a technology and infrastructure company focused on the development and commercialization of medical technology solutions. The company generates revenue primarily through the sale of its proprietary medical devices and related services, following its corporate rebrand from BioSig Technologies, Inc. in 2025.

Products and services

  • The company develops and markets medical technology, specifically focusing on electromedical and electrotherapeutic apparatus designed for clinical and diagnostic applications.

Customer types

Hospitals and clinical diagnostic centers.

Business strengths to evaluate

  • Proprietary medical technology intellectual property Source

Business risks and research considerations

  • History of operating losses and negative cash flow Source
  • Dependence on successful commercialization of medical devices Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

STEX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.52
Market capitalization:
53.85M (currency not supplied)
Revenue:
USD 146K
Net income:
USD -500.84M
Free cash flow:
USD -10.44M
Cash:
USD 5.61M
Total debt:
USD 800K
EPS:
USD -10.36

What stands out

  • Free cash flow is USD -10.44M, negative for the stored period.
  • The balance sheet shows USD 5.61M of cash versus USD 800K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -7148.6% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Cash exceeds debt by USD 4.81M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for STEX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can STEX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is STEX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for STEX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of STEX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research STEX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.